Isoket Lösung (Isosorbide Dinitrate)

Isosorbide dinitrate releases nitric oxide after metabolic conversion. The nitric oxide activates soluble guanylate cyclase, raising cyclic GMP levels in vascular smooth muscle. Elevated cyclic GMP causes relaxation of arteries and veins, producing vasodilation that lowers preload and afterload, thereby decreasing myocardial oxygen demand.

The specific dose of Isoket Lösung is individualized and set by the prescribing clinician based on the patient’s condition, response, and tolerance. Dosing regimens may vary for acute angina relief versus prophylactic use or heart‑failure management, and should follow local clinical guidelines.

Safety data for isosorbide dinitrate during pregnancy and lactation are limited. The product is classified as pregnancy category unknown, so it should only be used when the potential maternal benefit justifies any possible risk to the fetus. Breastfeeding mothers should consult their healthcare provider before use.

To order Isoket Lösung, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

The primary alternative to isosorbide dinitrate is nitroglycerin, another nitrate vasodilator. Both agents donate nitric oxide and cause vasodilation, but isosorbide dinitrate has a longer half‑life and more predictable plasma levels when given intravenously, making it useful for continuous infusion. Nitroglycerin may act more rapidly but often requires more frequent dosing.

Isoket Lösung should be stored at room temperature, below 25 °C, in its original container. Protect the solution from direct light, moisture, and extreme temperature fluctuations. Do not freeze the product, and keep it out of reach of children. Follow standard aseptic handling procedures when preparing for intravenous administration.

Isoket Lösung is administered intravenously by slow injection or continuous infusion, as directed by a qualified healthcare professional. The solution is typically diluted in a compatible IV fluid before infusion. Administration should be performed in a setting where blood pressure and cardiac status can be monitored closely.

Serious risks include profound hypotension that can lead to syncope, myocardial infarction or worsening ischemia due to reduced coronary perfusion, and life‑threatening arrhythmias such as ventricular tachycardia. Rarely, methemoglobinemia may develop. Immediate medical attention is required if any of these events occur.

Isoket Lösung is contraindicated in patients with known hypersensitivity to isosorbide dinitrate or other nitrates, those with severe hypotension (systolic blood pressure <90 mm Hg), recent myocardial infarction or unstable angina, and patients taking phosphodiesterase‑5 inhibitors. Caution is also advised for individuals with severe aortic stenosis or closed‑angle glaucoma.